Warwick J Britton

List of Publications by Year in Descending Order

247 papers	9,415 citations	49 h-index	90 g-index
277 ext. papers	10,751 ext. citations	6.7 avg, IF	6.02 L-index

#	Paper	IF	Citations
247	Common anti-haemostatic medications increase the severity of systemic infection by uropathogenic Escherichia coli. *Microbiological Research*, **2022**, 254, 126918	5.3	0
246	Immunological Assessment of Lung Responses to Inhalational Lipoprotein Vaccines Against Bacterial Pathogens. *Methods in Molecular Biology*, **2022**, 2414, 301-323	1.4	
245	Rough and smooth variants of Mycobacterium abscessus are differentially controlled by host immunity during chronic infection of adult zebrafish.. *Nature Communications*, **2022**, 13, 952	17.4	2
244	Pharmacokinetics and Safety of Inhaled Ivermectin in Mice as a Potential COVID-19 Treatment.. *International Journal of Pharmaceutics*, **2022**, 121688	6.5	0
243	Population-wide active case finding and prevention for tuberculosis and leprosy elimination in Kiribati: the PEARL study protocol.. *BMJ Open*, **2022**, 12, e055295	3	0
242	Inhibition of infection-induced vascular permeability modulates host leukocyte recruitment to Mycobacterium marinum granulomas in zebrafish.. *Pathogens and Disease*, **2022**,	4.2	1
241	Treatment of infection-induced vascular pathologies is protective against persistent rough morphotype Mycobacterium abscessus infection in zebrafish.. *Microbial Pathogenesis*, **2022**, 105590	3.8	0
240	Exposure to the gut microbiota from cigarette smoke-exposed mice exacerbates cigarette smoke extract-induced inflammation in zebrafish larvae.. *Current Research in Immunology*, **2021**, 2, 229-236	1	
239	Synthetic Sansanmycin Analogues as Potent Translocase I Inhibitors. *Journal of Medicinal Chemistry*, **2021**, 64, 17326-17345	8.3	2
238	Advances in the development of antimicrobial peptides and proteins for inhaled therapy. *Advanced Drug Delivery Reviews*, **2021**, 180, 114066	18.5	4
237	Boosting BCG with recombinant influenza A virus tuberculosis vaccines increases pulmonary T cell responses but not protection against Mycobacterium tuberculosis infection. *PLoS ONE*, **2021**, 16, e0259829	3.7	1
236	Advax adjuvant formulations promote protective immunity against aerosol Mycobacterium tuberculosis in the absence of deleterious inflammation and reactogenicity. *Vaccine*, **2021**, 39, 1990-1998	4.1	1
235	Mycobacterial infection-induced miR-206 inhibits protective neutrophil recruitment via the CXCL12/CXCR4 signalling axis. *PLoS Pathogens*, **2021**, 17, e1009186	7.6	3
234	TCR Affinity Controls the Dynamics but Not the Functional Specification of the Antimycobacterial CD4 T Cell Response. *Journal of Immunology*, **2021**,	5.3	1
233	Synergistic activity of phage PEV20-ciprofloxacin combination powder formulation-A proof-of-principle study in a P. aeruginosa lung infection model. *European Journal of Pharmaceutics and Biopharmaceutics*, **2021**, 158, 166-171	5.7	14
232	Mycobacterium ulcerans-specific immune response after immunisation with bacillus Calmette-Guﬁn (BCG) vaccine. *Vaccine*, **2021**, 39, 652-657	4.1	3
231	High sensitivity and specificity of a 5-analyte protein and microRNA biosignature for identification of active tuberculosis. *Clinical and Translational Immunology*, **2021**, 10, e1298	6.8	0

230	Synthetic protein conjugate vaccines provide protection against in mice. *Proceedings of the National Academy of Sciences of the United States of America*, **2021**, 118,	11.5	11
229	Intrapulmonary vaccination with delta-inulin adjuvant stimulates non-polarised chemotactic signalling and diverse cellular interaction. *Mucosal Immunology*, **2021**, 14, 762-773	9.2	3
228	Macrophages of different tissue origin exhibit distinct inflammatory responses to mycobacterial infection. *Immunology and Cell Biology*, **2021**, 99, 1085-1092	5	0
227	Particulate Mycobacterial Vaccines Induce Protective Immunity against Tuberculosis in Mice. *Nanomaterials*, **2021**, 11,	5.4	1
226	Effect of -Acetylcysteine in Combination with Antibiotics on the Biofilms of Three Cystic Fibrosis Pathogens of Emerging Importance. *Antibiotics*, **2021**, 10,	4.9	2
225	Haem oxygenase limits Mycobacterium marinum infection-induced detrimental ferrostatin-sensitive cell death in zebrafish. *FEBS Journal*, **2021**,	5.7	1
224	Glucose inhibits haemostasis and accelerates diet-induced hyperlipidaemia in zebrafish larvae. *Scientific Reports*, **2021**, 11, 19049	4.9	1
223	Mucosal delivery of a multistage subunit vaccine promotes development of lung-resident memory T cells and affords interleukin-17-dependent protection against pulmonary tuberculosis. *Npj Vaccines*, **2020**, 5, 105	9.5	23
222	CD103+ tumor-resident CD8+ T cell numbers underlie improved patient survival in oropharyngeal squamous cell carcinoma **2020**, 8,		7
221	Levofloxacin versus placebo for the treatment of latent tuberculosis among contacts of patients with multidrug-resistant tuberculosis (the VQUIN MDR trial): a protocol for a randomised controlled trial. *BMJ Open*, **2020**, 10, e033945	3	8
220	Total Synthesis and Antimycobacterial Activity of Ohmyungsamycin A, Deoxyecumicin, and Ecumicin. *Chemistry - A European Journal*, **2020**, 26, 15200-15205	4.8	4
219	A transcriptional blood signature distinguishes early tuberculosis disease from latent tuberculosis infection and uninfected individuals in a Vietnamese cohort. *Journal of Infection*, **2020**, 81, 72-80	18.9	7
218	Conserved anti-inflammatory effects and sensing of butyrate in zebrafish. *Gut Microbes*, **2020**, 12, 1-11	8.8	14
217	Can bacteriophage endolysins be nebulised for inhalation delivery against Streptococcus pneumoniae?. *International Journal of Pharmaceutics*, **2020**, 591, 119982	6.5	4
216	Storage stability of phage-ciprofloxacin combination powders against Pseudomonas aeruginosa respiratory infections. *International Journal of Pharmaceutics*, **2020**, 591, 119952	6.5	6
215	Animal and translational models of SARS-CoV-2 infection and COVID-19. *Mucosal Immunology*, **2020** , 13, 877-891	9.2	106
214	Community-wide Screening for Tuberculosis in a High-Prevalence Setting. *New England Journal of Medicine*, **2019**, 381, 1347-1357	59.2	58
213	CXCR6-Deficiency Improves the Control of Pulmonary and Influenza Infection Independent of T-Lymphocyte Recruitment to the Lungs. *Frontiers in Immunology*, **2019**, 10, 339	8.4	18

212	The cyclic nitroxide antioxidant 4-methoxy-TEMPO decreases mycobacterial burden in vivo through host and bacterial targets. *Free Radical Biology and Medicine*, **2019**, 135, 157-166	7.8	6
211	Thrombocyte Inhibition Restores Protective Immunity to Mycobacterial Infection in Zebrafish. *Journal of Infectious Diseases*, **2019**, 220, 524-534	7	20
210	Deciphering protective immunity against tuberculosis: implications for vaccine development. *Expert Review of Vaccines*, **2019**, 18, 353-364	5.2	16
209	Storage stability of inhalable phage powders containing lactose at ambient conditions. *International Journal of Pharmaceutics*, **2019**, 560, 11-18	6.5	25
208	Mycobacterium tuberculosis requires glyoxylate shunt and reverse methylcitrate cycle for lactate and pyruvate metabolism. *Molecular Microbiology*, **2019**, 112, 1284-1307	4.1	39
207	Inhalable combination powder formulations of phage and ciprofloxacin for P. aeruginosa respiratory infections. *European Journal of Pharmaceutics and Biopharmaceutics*, **2019**, 142, 543-552	5.7	28
206	Mucosal Vaccination with a Self-Adjuvanted Lipopeptide Is Immunogenic and Protective against. *Journal of Medicinal Chemistry*, **2019**, 62, 8080-8089	8.3	17
205	Australian adults with bronchiectasis: The first report from the Australian Bronchiectasis Registry. *Respiratory Medicine*, **2019**, 155, 97-103	4.6	19
204	Management of Australian Adults with Bronchiectasis in Tertiary Care: Evidence-Based or Access-Driven?. *Lung*, **2019**, 197, 803-810	2.9	5
203	Visualizing the Selectivity and Dynamics of Interferon Signaling In Vivo. *Cell Reports*, **2019**, 29, 3539-3550.e4	8.4	11
202	Jet nebulization of bacteriophages with different tail morphologies - Structural effects. *International Journal of Pharmaceutics*, **2019**, 554, 322-326	6.5	17
201	Effect of storage temperature on the stability of spray dried bacteriophage powders. *European Journal of Pharmaceutics and Biopharmaceutics*, **2018**, 127, 213-222	5.7	35
200	Protective efficacy of recombinant BCG over-expressing protective, stage-specific antigens of Mycobacterium tuberculosis. *Vaccine*, **2018**, 36, 2619-2629	4.1	8
199	Household-Contact Investigation for Detection of Tuberculosis in Vietnam. *New England Journal of Medicine*, **2018**, 378, 221-229	59.2	101
198	Total Synthesis of Ecumicin. *Organic Letters*, **2018**, 20, 1019-1022	6.2	14
197	A proline deletion in IFNAR1 impairs IFN-signaling and underlies increased resistance to tuberculosis in humans. *Nature Communications*, **2018**, 9, 85	17.4	26
196	CD103 Tumor-Resident CD8 T Cells Are Associated with Improved Survival in Immunotherapy-Naïve Melanoma Patients and Expand Significantly During Anti-PD-1 Treatment. *Clinical Cancer Research*, **2018**, 24, 3036-3045	12.9	163
195	Mycobacterium marinum infection drives foam cell differentiation in zebrafish infection models. *Developmental and Comparative Immunology*, **2018**, 88, 169-172	3.2	16

194	Childhood fish oil supplementation modifies associations between traffic related air pollution and allergic sensitisation. *Environmental Health*, **2018**, 17, 27	6	8
193	Microfluidic-assisted bacteriophage encapsulation into liposomes. *International Journal of Pharmaceutics*, **2018**, 545, 176-182	6.5	18
192	Identification of a plasma microRNA profile in untreated pulmonary tuberculosis patients that is modulated by anti-mycobacterial therapy. *Journal of Infection*, **2018**, 77, 341-348	18.9	16
191	Pulmonary immunization with a recombinant influenza A virus vaccine induces lung-resident CD4 memory T cells that are associated with protection against tuberculosis. *Mucosal Immunology*, **2018** , 11, 1743-1752	9.2	30
190	PLGA particulate subunit tuberculosis vaccines promote humoral and Th17 responses but do not enhance control of Mycobacterium tuberculosis infection. *PLoS ONE*, **2018**, 13, e0194620	3.7	21
189	Proof-of-Principle Study in a Murine Lung Infection Model of Antipseudomonal Activity of Phage PEV20 in a Dry-Powder Formulation. *Antimicrobial Agents and Chemotherapy*, **2018**, 62,	5.9	38
188	Analysis of mycobacterial infection-induced changes to host lipid metabolism in a zebrafish infection model reveals a conserved role for LDLR in infection susceptibility. *Fish and Shellfish Immunology*, **2018**, 83, 238-242	4.3	7
187	Synergy of nebulized phage PEV20 and ciprofloxacin combination against Pseudomonas aeruginosa. *International Journal of Pharmaceutics*, **2018**, 551, 158-165	6.5	46
186	Thioamide Derivative of the Potent Antitubercular 2-(Decylsulfonyl)acetamide is Less Active Against Mycobacterium tuberculosis, but a More Potent Antistaphylococcal Agent. *Australian Journal of Chemistry*, **2018**, 71, 716	1.2	3
185	Cohort profile: The Childhood Asthma Prevention Study (CAPS). *International Journal of Epidemiology*, **2018**, 47, 1736-1736k	7.8	5
184	Sansanmycin natural product analogues as potent and selective anti-mycobacterials that inhibit lipid I biosynthesis. *Nature Communications*, **2017**, 8, 14414	17.4	31
183	Effects of storage conditions on the stability of spray dried, inhalable bacteriophage powders. *International Journal of Pharmaceutics*, **2017**, 521, 141-149	6.5	56
182	Inhalation of Respirable Crystalline Rifapentine Particles Induces Pulmonary Inflammation. *Molecular Pharmaceutics*, **2017**, 14, 328-335	5.6	11
181	Synthesis of Norfijimycin A with Activity against Mycobacterium tuberculosis. *Australian Journal of Chemistry*, **2017**, 70, 229	1.2	2
180	Protein Transport in Mycobacterium tuberculosis **2017**, 111-130		
179	The Proteome of Mycobacterium tuberculosis in Three Dimensions **2017**, 261-285		
178	Biochemistry of the Cell Envelope of Mycobacterium tuberculosis **2017**, 1-19		2
177	Polyketides and Polyketide-Containing Glycolipids of Mycobacterium tuberculosis: Structure, Biosynthesis and Biological Activities **2017**, 21-51		4

176	Physiology of Mycobacterium tuberculosis **2017**, 53-69		3
175	Human CD4 and CD8 T Cell Responses to Mycobacterium tuberculosis: Antigen Specificity, Function, Implications and Applications **2017**, 119-155		4
174	Genomics of the Mycobacterium tuberculosis Complex **2017**, 193-211		
173	Mechanisms of Drug Action, Drug Resistance and Drug Tolerance in Mycobacterium tuberculosis: Expected Phenotypes from Evolutionary Pressures from a Highly Successful Pathogen **2017**, 323-378		4
172	Mycobacterium tuberculosis Interactions with Dendritic Cells and Macrophages **2017**, 45-59		2
171	Killing Mechanisms of the Host Against Mycobacterium tuberculosis **2017**, 61-89		1
170	The PE and PPE Protein Families of Mycobacterium tuberculosis **2017**, 131-150		11
169	Mycobacterium tuberculosis: Life and Death in the Phagosome **2017**, 307-322		4
168	Determinants of Phagocytosis, Phagosome Biogenesis and Autophagy for Mycobacterium tuberculosis **2017**, 1-22		12
167	Manipulation of the Macrophage Response by Pathogenic Mycobacteria **2017**, 91-117		2
166	Genetic Control of Host Susceptibility to Tuberculosis **2017**, 305-346		4
165	Nutrient Uptake by Mycobacteria **2017**, 71-89		
164	Mathematical Modeling of Tuberculosis Transmission Dynamics **2017**, 227-243		2
163	Proteomics of Mycobacterium tuberculosis **2017**, 241-260		
162	Delta inulin-based adjuvants promote the generation of polyfunctional CD4 T cell responses and protection against Mycobacterium tuberculosis infection. *Scientific Reports*, **2017**, 7, 8582	4.9	40
161	Transcriptomics and Transcriptional Regulation **2017**, 213-240		
160	Experimental Genetics of Mycobacterium tuberculosis **2017**, 379-391		
159	Dendritic Cells Inflammatory Signature Induced by Microbial Pathogens **2017**, 23-44		

158	Unconventional T Cells **2017**, 157-183		4
157	The Antibody Response to Infection with Mycobacterium tuberculosis **2017**, 227-244		1
156	Maintenance of Latent Infection, with Correlates of Protective Immunity **2017**, 279-304		
155	Tuberculosis/Human Immunodeficiency Virus Coinfection and the Host Immune Response **2017**, 347-368		4
154	Novel Vaccination Strategies Against Tuberculosis **2017**, 369-387		
153	BCG Vaccination: Epidemiology and Immunology **2017**, 245-276		
152	Tuberculosis Control: Good Clinical Care and Good Public Health **2017**, 115-130		
151	Clinical Management of Multidrug-Resistant Tuberculosis **2017**, 181-211		
150	Novel Treatment Strategies for TB Patients with HIV Co-infection **2017**, 213-225		
149	Iron Uptake by Mycobacterium tuberculosis **2017**, 91-110		1
148	Experimental Animal Models of Tuberculosis **2017**, 389-426		18
147	Production of highly stable spray dried phage formulations for treatment of Pseudomonas aeruginosa lung infection. *European Journal of Pharmaceutics and Biopharmaceutics*, **2017**, 121, 1-13	5.7	54
146	Modulation of Roquin Function in Myeloid Cells Reduces -Induced Inflammation. *Journal of Immunology*, **2017**, 199, 1796-1804	5.3	1
145	A Liver Capsular Network of Monocyte-Derived Macrophages Restricts Hepatic Dissemination of Intraperitoneal Bacteria by Neutrophil Recruitment. *Immunity*, **2017**, 47, 374-388.e6	32.3	94
144	Anti-Tuberculosis Bacteriophage D29 Delivery with a Vibrating Mesh Nebulizer, Jet Nebulizer, and Soft Mist Inhaler. *Pharmaceutical Research*, **2017**, 34, 2084-2096	4.5	44
143	Mycobacterium tuberculosis Infection Manipulates the Glycosylation Machinery and the N-Glycoproteome of Human Macrophages and Their Microparticles. *Journal of Proteome Research*, **2017**, 16, 247-263	5.6	30
142	The Delivery of High-Dose Dry Powder Antibiotics by a Low-Cost Generic Inhaler. *AAPS Journal*, **2017**, 19, 191-202	3.7	12
141	Molecular Mechanisms of Dormancy and Resuscitation **2017**, 287-306		

140	Virulence and Persistence Mechanisms of Mycobacterium tuberculosis **2017**, 151-191		1
139	Clinical Features of Tuberculosis **2017**, 89-113		1
138	Molecular Evolution of Mycobacteria **2017**, 393-416		3
137	Surveillance Studies and Interpretation **2017**, 23-40		
136	Molecular Epidemiology of Mycobacterium tuberculosis **2017**, 41-62		1
135	TB Drug Discovery from Target Identification to Proof of Concept Studies **2017**, 143-163		
134	Latent Tuberculosis Infection **2017**, 165-180		1
133	Global Epidemiology and Control of Tuberculosis **2017**, 1-21		1
132	Immunopathology of Tuberculosis **2017**, 245-278		5
131	Clinical Diagnosis of M. tuberculosis Infection **2017**, 63-87		
130	Chemotherapy of Tuberculosis **2017**, 131-142		
129	Comparable CD4 and CD8 T cell responses and cytokine release after at-birth and delayed BCG immunisation in infants born in Australia. *Vaccine*, **2016**, 34, 4132-4139	4.1	10
128	components expressed during chronic infection of the lung contribute to long-term control of pulmonary tuberculosis in mice. *Npj Vaccines*, **2016**, 1, 16012	9.5	19
127	Compartmentalization of Total and Virus-Specific Tissue-Resident Memory CD8+ T Cells in Human Lymphoid Organs. *PLoS Pathogens*, **2016**, 12, e1005799	7.6	57
126	Functional Interplay between Type I and II Interferons Is Essential to Limit Influenza A Virus-Induced Tissue Inflammation. *PLoS Pathogens*, **2016**, 12, e1005378	7.6	40
125	Total Synthesis of Teixobactin. *Organic Letters*, **2016**, 18, 2788-91	6.2	70
124	Dry powder inhalable formulations for anti-tubercular therapy. *Advanced Drug Delivery Reviews*, **2016**, 102, 83-101	18.5	47
123	Rifapentine-loaded PLGA microparticles for tuberculosis inhaled therapy: Preparation and in vitro aerosol characterization. *European Journal of Pharmaceutical Sciences*, **2016**, 88, 1-11	5.1	35

122	Production of Inhalation Phage Powders Using Spray Freeze Drying and Spray Drying Techniques for Treatment of Respiratory Infections. *Pharmaceutical Research*, **2016**, 33, 1486-96	4.5	83
121	Influence of phthiocerol dimycocerosate on CD4(+) T cell priming and persistence during Mycobacterium tuberculosis infection. *Tuberculosis*, **2016**, 99, 25-30	2.6	0
120	Epitope-specific CD4+, but not CD8+, T-cell responses induced by recombinant influenza A viruses protect against Mycobacterium tuberculosis infection. *European Journal of Immunology*, **2015**, 45, 780-93	6.1	19
119	Microparticles released from Mycobacterium tuberculosis-infected human macrophages contain increased levels of the type I interferon inducible proteins including ISG15. *Proteomics*, **2015**, 15, 3020-9	4.8	27
118	Identification of miR-93 as a suitable miR for normalizing miRNA in plasma of tuberculosis patients. *Journal of Cellular and Molecular Medicine*, **2015**, 19, 1606-13	5.6	34
117	Murine pharmacokinetics of rifapentine delivered as an inhalable dry powder. *International Journal of Antimicrobial Agents*, **2015**, 45, 319-23	14.3	8
116	A rifapentine-containing inhaled triple antibiotic formulation for rapid treatment of tubercular infection. *Pharmaceutical Research*, **2014**, 31, 1239-53	4.5	36
115	A novel inhalable form of rifapentine. *Journal of Pharmaceutical Sciences*, **2014**, 103, 1411-21	3.9	32
114	Current transmission prevention methods: reducing disease spread from infected individuals **2014**, 53-75		1
113	Polymorphisms of SP110 are associated with both pulmonary and extra-pulmonary tuberculosis among the Vietnamese. *PLoS ONE*, **2014**, 9, e99496	3.7	20
112	Pathology and Pathogenesis of Bacterial Infections **2014**, 325-336		
111	TLR2-targeted secreted proteins from Mycobacterium tuberculosis are protective as powdered pulmonary vaccines. *Vaccine*, **2013**, 31, 4322-9	4.1	42
110	Inhibition studies on Mycobacterium tuberculosis N-acetylglucosamine-1-phosphate uridyltransferase (GlmU). *Organic and Biomolecular Chemistry*, **2013**, 11, 8113-26	3.9	21
109	Household contact investigation for tuberculosis in Vietnam: study protocol for a cluster randomized controlled trial. *Trials*, **2013**, 14, 342	2.8	12
108	Microparticles from mycobacteria-infected macrophages promote inflammation and cellular migration. *Journal of Immunology*, **2013**, 190, 669-77	5.3	44
107	Host cell-induced components of the sulfate assimilation pathway are major protective antigens of Mycobacterium tuberculosis. *Journal of Infectious Diseases*, **2013**, 207, 778-85	7	11
106	Reply: Bacille Calmette-Guérin vaccine: innate immunity and nonspecific effects. *American Journal of Respiratory and Critical Care Medicine*, **2013**, 187, 779-80	10.2	3
105	Contact investigation for tuberculosis: a systematic review and meta-analysis. *European Respiratory Journal*, **2013**, 41, 140-56	13.6	413

104	Influenza A virus infection impairs mycobacteria-specific T cell responses and mycobacterial clearance in the lung during pulmonary coinfection. *Journal of Immunology*, **2013**, 191, 302-11	5.3	28
103	Total synthesis of fellutamide B and deoxy-fellutamides B, C, and D. *Marine Drugs*, **2013**, 11, 2382-97	6	12
102	Harnessing single cell sorting to identify cell division genes and regulators in bacteria. *PLoS ONE*, **2013**, 8, e60964	3.7	22
101	Bug breakfast in the bulletin: leprosy. *NSW Public Health Bulletin*, **2013**, 24, 50		
100	Protective immunity afforded by attenuated, PhoP-deficient Mycobacterium tuberculosis is associated with sustained generation of CD4+ T-cell memory. *European Journal of Immunology*, **2012**, 42, 385-92	6.1	40
99	The influence of bacille Calmette-Guerin vaccine strain on the immune response against tuberculosis: a randomized trial. *American Journal of Respiratory and Critical Care Medicine*, **2012**, 185, 213-22	10.2	89
98	Synthesis and evaluation of M. tuberculosis salicylate synthase (MbtI) inhibitors designed to probe plasticity in the active site. *Organic and Biomolecular Chemistry*, **2012**, 10, 9223-36	3.9	16
97	M. tuberculosis induces potent activation of IDO-1, but this is not essential for the immunological control of infection. *PLoS ONE*, **2012**, 7, e37314	3.7	61
96	Elucidation of Mycobacterium tuberculosis type II dehydroquinase inhibitors using a fragment elaboration strategy. *ChemMedChem*, **2012**, 7, 1031-43	3.7	12
95	The secreted lipoprotein, MPT83, of Mycobacterium tuberculosis is recognized during human tuberculosis and stimulates protective immunity in mice. *PLoS ONE*, **2012**, 7, e34991	3.7	27
94	A comparative analysis of polyfunctional T cells and secreted cytokines induced by Bacille Calmette-Guﬁn immunisation in children and adults. *PLoS ONE*, **2012**, 7, e37535	3.7	24
93	Delivery of a multivalent scrambled antigen vaccine induces broad spectrum immunity and protection against tuberculosis. *Vaccine*, **2011**, 29, 7759-65	4.1	11
92	Inhibitors of an essential mycobacterial cell wall lipase (Rv3802c) as tuberculosis drug leads. *Chemical Communications*, **2011**, 47, 5166-8	5.8	32
91	Synthesis and evaluation of potent ene-yne inhibitors of type II dehydroquinases as tuberculosis drug leads. *ChemMedChem*, **2011**, 6, 262-5	3.7	9
90	Mycobacterium bovis BCG-specific Th17 cells confer partial protection against Mycobacterium tuberculosis infection in the absence of gamma interferon. *Infection and Immunity*, **2010**, 78, 4187-94	3.7	103
89	LIGHT contributes to early but not late control of Mycobacterium tuberculosis infection. *International Immunology*, **2010**, 22, 353-8	4.9	7
88	Tetrahydrolipstatin inhibition, functional analyses, and three-dimensional structure of a lipase essential for mycobacterial viability. *Journal of Biological Chemistry*, **2010**, 285, 30050-60	5.4	27
87	In vivo persistence and protective efficacy of the bacille Calmette Guerin vaccine overexpressing the HspX latency antigen. *Bioengineered Bugs*, **2010**, 1, 61-5		18

86	Cutinase-like protein-6 of Mycobacterium tuberculosis is recognised in tuberculosis patients and protects mice against pulmonary infection as a single and fusion protein vaccine. *Vaccine*, **2010**, 28, 1341-6	4.1	14
85	Rapid assembly of potent type II dehydroquinase inhibitorsvia "click" chemistry. *MedChemComm*, **2010**, 1, 271-275	5	14
84	Modulation of pulmonary DC function by vaccine-encoded GM-CSF enhances protective immunity against Mycobacterium tuberculosis infection. *European Journal of Immunology*, **2010**, 40, 153-61	6.1	42
83	Cutinase-like proteins of Mycobacterium tuberculosis: characterization of their variable enzymatic functions and active site identification. *FASEB Journal*, **2009**, 23, 1694-704	0.9	55
82	Antigen load governs the differential priming of CD8 T cells in response to the bacille Calmette Guerin vaccine or Mycobacterium tuberculosis infection. *Journal of Immunology*, **2009**, 182, 7172-7	5.3	54
81	Gene expression in HIV-1/Mycobacterium tuberculosis co-infected macrophages is dominated by M. tuberculosis. *Tuberculosis*, **2009**, 89, 285-93	2.6	21
80	Lymphotoxin-alpha and TNF have essential but independent roles in the evolution of the granulomatous response in experimental leprosy. *American Journal of Pathology*, **2009**, 174, 1379-89	5.8	26
79	Comparison of IFN-gamma responses to mycobacterial antigens as markers of response to BCG vaccination. *Tuberculosis*, **2008**, 88, 31-8	2.6	15
78	Immunological diversity within a family of cutinase-like proteins of Mycobacterium tuberculosis. *Vaccine*, **2008**, 26, 3853-9	4.1	25
77	Influence of BCG vaccine strain on the immune response and protection against tuberculosis. *FEMS Microbiology Reviews*, **2008**, 32, 821-41	15.1	115
76	IL-5 T-cell responses to house dust mite are associated with the development of allergen-specific IgE responses and asthma in the first 5 years of life. *Journal of Allergy and Clinical Immunology*, **2007** , 120, 286-92	11.5	15
75	Life and death in the granuloma: immunopathology of tuberculosis. *Immunology and Cell Biology*, **2007**, 85, 103-11	5	225
74	Early predictors for developing allergic disease and asthma: examining separate steps in the 'allergic march'. *Clinical and Experimental Allergy*, **2007**, 37, 1296-302	4.1	74
73	Improved protection against disseminated tuberculosis by Mycobacterium bovis bacillus Calmette-Guerin secreting murine GM-CSF is associated with expansion and activation of APCs. *Journal of Immunology*, **2007**, 179, 8418-24	5.3	36
72	Secretion of functional monocyte chemotactic protein 3 by recombinant Mycobacterium bovis BCG attenuates vaccine virulence and maintains protective efficacy against M. tuberculosis infection. *Infection and Immunity*, **2007**, 75, 523-6	3.7	16
71	Effects of DNA- and Mycobacterium bovis BCG-based delivery of the Flt3 ligand on protective immunity to Mycobacterium tuberculosis. *Infection and Immunity*, **2007**, 75, 5368-75	3.7	26
70	A polymorphism in the P2X7 gene increases susceptibility to extrapulmonary tuberculosis. *American Journal of Respiratory and Critical Care Medicine*, **2007**, 175, 360-6	10.2	175
69	Differential requirements for soluble and transmembrane tumor necrosis factor in the immunological control of primary and secondary Listeria monocytogenes infection. *Infection and Immunity*, **2006**, 74, 3180-9	3.7	28

68	Plasmid interleukin-23 (IL-23), but not plasmid IL-27, enhances the protective efficacy of a DNA vaccine against Mycobacterium tuberculosis infection. *Infection and Immunity*, **2006**, 74, 557-65	3.7	69
67	Contribution of L-alanine dehydrogenase to in vivo persistence and protective efficacy of the BCG vaccine. *Microbiology and Immunology*, **2006**, 50, 805-10	2.7	5
66	Interleukin-23 restores immunity to Mycobacterium tuberculosis infection in IL-12p40-deficient mice and is not required for the development of IL-17-secreting T cell responses. *Journal of Immunology*, **2006**, 177, 8684-92	5.3	84
65	A Thr357 to Ser polymorphism in homozygous and compound heterozygous subjects causes absent or reduced P2X7 function and impairs ATP-induced mycobacterial killing by macrophages. *Journal of Biological Chemistry*, **2006**, 281, 2079-86	5.4	133
64	Genetic susceptibility to mycobacterial disease in humans. *Immunology and Cell Biology*, **2006**, 84, 125-37	5	62
63	Single chain antibody fragments for the selective targeting of antigens to dendritic cells. *Molecular Immunology*, **2005**, 42, 979-85	4.3	66
62	Expanding the antigenic repertoire of BCG improves protective efficacy against aerosol Mycobacterium tuberculosis infection. *Vaccine*, **2005**, 23, 1680-5	4.1	34
61	Epitope-tagging vectors for the expression and detection of recombinant proteins in mycobacteria. *Plasmid*, **2005**, 53, 269-73	3.3	11
60	Gene dosage determines the negative effects of polymorphic alleles of the P2X7 receptor on adenosine triphosphate-mediated killing of mycobacteria by human macrophages. *Journal of Infectious Diseases*, **2005**, 192, 149-55	7	63
59	Transmembrane TNF is sufficient to initiate cell migration and granuloma formation and provide acute, but not long-term, control of Mycobacterium tuberculosis infection. *Journal of Immunology*, **2005**, 174, 4852-9	5.3	133
58	Vaccines for other neonatal infections: neonatal BCG vaccination against tuberculosis. *Expert Review of Vaccines*, **2004**, 3, 365-9	5.2	
57	The Mycobacterium tuberculosis cysD and cysNC genes form a stress-induced operon that encodes a tri-functional sulfate-activating complex. *Microbiology (United Kingdom)*, **2004**, 150, 1681-1686	2.9	61
56	Mycobacterium tuberculosis defective in phthiocerol dimycocerosate translocation provides greater protective immunity against tuberculosis than the existing bacille Calmette-Guérin vaccine. *Journal of Infectious Diseases*, **2004**, 189, 105-12	7	39
55	Targeting dendritic cells with antigen-containing liposomes: a highly effective procedure for induction of antitumor immunity and for tumor immunotherapy. *Cancer Research*, **2004**, 64, 4357-65	10.1	223
54	T cell-derived tumour necrosis factor is essential, but not sufficient, for protection against Mycobacterium tuberculosis infection. *Clinical and Experimental Immunology*, **2004**, 137, 279-87	6.2	48
53	Leprosy. *Lancet, The*, **2004**, 363, 1209-19	40	539
52	A loss-of-function polymorphism in the human P2X7 receptor abolishes ATP-mediated killing of mycobacteria. *Journal of Immunology*, **2003**, 171, 5442-6	5.3	103
51	Identification of strong promoter elements of Mycobacterium smegmatis and their utility for foreign gene expression in mycobacteria. *FEMS Microbiology Letters*, **2003**, 224, 139-42	2.9	11

50	Improving vaccines against tuberculosis. *Immunology and Cell Biology*, **2003**, 81, 34-45	5	50
49	The combination of plasmid interleukin-12 with a single DNA vaccine is more effective than Mycobacterium bovis (bacille Calmette-Guﬁn) in protecting against systemic Mycobacterim avium infection. *Immunology*, **2003**, 109, 308-14	7.8	24
48	Eighteen-month outcomes of house dust mite avoidance and dietary fatty acid modification in the Childhood Asthma Prevention Study (CAPS). *Journal of Allergy and Clinical Immunology*, **2003**, 111, 162-8	11.5	165
47	The effect of neonatal BCG vaccination on atopy and asthma at age 7 to 14 years: an historical cohort study in a community with a very low prevalence of tuberculosis infection and a high prevalence of atopic disease. *Journal of Allergy and Clinical Immunology*, **2003**, 111, 541-9	11.5	106
46	Gamma interferon responses induced by a panel of recombinant and purified mycobacterial antigens in healthy, non-mycobacterium bovis BCG-vaccinated Malawian young adults. *Vaccine Journal*, **2003**, 10, 602-11		32
45	Autocrine IL-10 impairs dendritic cell (DC)-derived immune responses to mycobacterial infection by suppressing DC trafficking to draining lymph nodes and local IL-12 production. *European Journal of Immunology*, **2002**, 32, 994-1002	6.1	161
44	Comparative affects of plasmid-encoded interleukin 12 and interleukin 18 on the protective efficacy of DNA vaccination against Mycobacterium tuberculosis. *Immunology and Cell Biology*, **2002** , 80, 346-50	5	30
43	Characterization of immune responses during infection with Mycobacterium avium strains 100, 101 and the recently sequenced 104. *Immunology and Cell Biology*, **2002**, 80, 544-9	5	13
42	Lymphocyte recruitment and protective efficacy against pulmonary mycobacterial infection are independent of the route of prior Mycobacterium bovis BCG immunization. *Infection and Immunity*, **2002**, 70, 1410-6	3.7	45
41	TNF regulates chemokine induction essential for cell recruitment, granuloma formation, and clearance of mycobacterial infection. *Journal of Immunology*, **2002**, 168, 4620-7	5.3	538
40	Coexpression of interleukin-12 chains by a self-splicing vector increases the protective cellular immune response of DNA and Mycobacterium bovis BCG vaccines against Mycobacterium tuberculosis. *Infection and Immunity*, **2002**, 70, 1949-56	3.7	48
39	Destabilized green fluorescent protein for monitoring transient changes in mycobacterial gene expression. *Research in Microbiology*, **2002**, 153, 379-83	4	15
38	Induction of CD8+ T-lymphocyte responses to a secreted antigen of Mycobacterium tuberculosis by an attenuated vaccinia virus. *Immunology and Cell Biology*, **2001**, 79, 569-75	5	18
37	Stimulation of dendritic cells via CD40 enhances immune responses to Mycobacterium tuberculosis infection. *Infection and Immunity*, **2001**, 69, 2456-61	3.7	52
36	Priming by DNA immunization augments protective efficacy of Mycobacterium bovis Bacille Calmette-Guerin against tuberculosis. *Infection and Immunity*, **2001**, 69, 4174-6	3.7	109
35	Dendritic cells infected with Mycobacterium bovis bacillus Calmette Guerin activate CD8(+) T cells with specificity for a novel mycobacterial epitope. *International Immunology*, **2001**, 13, 451-8	4.9	37
34	Secreted lymphotoxin-alpha is essential for the control of an intracellular bacterial infection. *Journal of Experimental Medicine*, **2001**, 193, 239-46	16.6	138
33	Isolation of strong expression signals of Mycobacterium tuberculosis. *Microbiology (United Kingdom)*, **2001**, 147, 1253-1258	2.9	20

32	Protective effect of DNA immunization against mycobacterial infection is associated with the early emergence of interferon-gamma (IFN-gamma)-secreting lymphocytes. *Clinical and Experimental Immunology*, **2000**, 120, 476-82	6.2	34
31	Interaction of dendritic cells with mycobacteria: where the action starts. *Immunology and Cell Biology*, **2000**, 78, 318-24	5	70
30	Up-regulation of VCAM-1 and differential expansion of beta integrin-expressing T lymphocytes are associated with immunity to pulmonary Mycobacterium tuberculosis infection. *Journal of Immunology*, **2000**, 164, 4853-60	5.3	79
29	Protection against virulent Mycobacterium avium infection following DNA vaccination with the 35-kilodalton antigen is accompanied by induction of gamma interferon-secreting CD4(+) T cells. *Infection and Immunity*, **2000**, 68, 3090-6	3.7	30
28	Ischaemic peripheral neuritis secondary to ergotism associated with ritonavir therapy. *Medical Journal of Australia*, **1999**, 171, 502, 504	4	6
27	Co-immunization with DNA vaccines expressing granulocyte-macrophage colony-stimulating factor and mycobacterial secreted proteins enhances T-cell immunity, but not protective efficacy against Mycobacterium tuberculosis. *Immunology*, **1999**, 96, 511-6	7.8	61
26	Protection against aerosol Mycobacterium tuberculosis infection using Mycobacterium bovis Bacillus Calmette Guﬁn-infected dendritic cells. *European Journal of Immunology*, **1999**, 29, 1972-9	6.1	130
25	Differential Protective Efficacy of DNA Vaccines Expressing Secreted Proteins of Mycobacterium tuberculosis. *Infection and Immunity*, **1999**, 67, 1702-1707	3.7	11
24	Differential protective efficacy of DNA vaccines expressing secreted proteins of Mycobacterium tuberculosis. *Infection and Immunity*, **1999**, 67, 1702-7	3.7	234
23	Increase in gamma interferon-secreting CD8(+), as well as CD4(+), T cells in lungs following aerosol infection with Mycobacterium tuberculosis. *Infection and Immunity*, **1999**, 67, 3242-7	3.7	111
22	Protection against aerosol Mycobacterium tuberculosis infection using Mycobacterium bovis Bacillus Calmette Guﬁn-infected dendritic cells **1999**, 29, 1972		6
21	An inducible expression system permitting the efficient purification of a recombinant antigen from Mycobacterium smegmatis. *FEMS Microbiology Letters*, **1998**, 167, 151-6	2.9	128
20	Molecular and immunological analyses of the Mycobacterium avium homolog of the immunodominant Mycobacterium leprae 35-kilodalton protein. *Infection and Immunity*, **1998**, 66, 2684-90	3.7	29
19	Specific serological diagnosis of leprosy with a recombinant Mycobacterium leprae protein purified from a rapidly growing mycobacterial host. *Journal of Clinical Microbiology*, **1998**, 36, 2363-5	9.7	12
18	The management of leprosy reversal reactions. *Leprosy Review*, **1998**, 69, 225-34	0.6	36
17	Rapid effector function in CD8+ memory T cells. *Journal of Experimental Medicine*, **1997**, 186, 859-65	16.6	581
16	The spectrum of primary immunodeficiency disorders in Australia. *Journal of Allergy and Clinical Immunology*, **1997**, 100, 415-23	11.5	62
15	Analysis of the internal transcribed spacer regions of ribosomal DNA in common airborne allergenic fungi. *Electrophoresis*, **1997**, 18, 1567-9	3.6	25

14	The immune response to mycobacterial 70-kDa heat shock proteins frequently involves autoreactive T cells and is quantitatively disregulated in multiple sclerosis. *Journal of Neuroimmunology*, **1996**, 65, 143-53	3.5	49
13	Characterization of the gene encoding the immunodominant 35 kDa protein of Mycobacterium leprae. *Molecular Microbiology*, **1995**, 16, 865-76	4.1	47
12	Mechanisms of persistence of mycobacteria. *Trends in Microbiology*, **1994**, 2, 284-8	12.4	43
11	Subclinical infection with Mycobacterium leprae--a problem for leprosy control strategies. *Transactions of the Royal Society of Tropical Medicine and Hygiene*, **1993**, 87, 412-5	2	19
10	Immunology of leprosy. *Transactions of the Royal Society of Tropical Medicine and Hygiene*, **1993**, 87, 508-14	2	26
9	The response to chemotherapy of serum Mycobacterium leprae-specific antigen in multibacillary leprosy patients. *American Journal of Tropical Medicine and Hygiene*, **1991**, 44, 702-8	3.2	3
8	Human T-cell clones recognize a major M. leprae protein antigen expressed in E. coli. *Nature*, **1986**, 319, 63-6	50.4	145
7	Mucosal delivery of a multistage subunit vaccine promotes development of lung-resident memory T cells and affords interleukin-17-dependant protection against pulmonary tuberculosis		1
6	Advax adjuvant formulations promote protective immunity against aerosol Mycobacterium tuberculosis in the absence of deleterious inflammation and reactogenicity		1
5	Mycobacterial infection-induced miR-206 inhibits protective neutrophil recruitment via the CXCL12/CXCR4 signalling axis		2
4	Thrombocyte inhibition restores protective immunity to mycobacterial infection in zebrafish		1
3	Rough and smooth variant Mycobacterium abscessus infections are differentially controlled by host immunity during chronic infection		1
2	The Constituents of the Cell Envelope and Their Impact on the Host Immune System249-270		
1	OXSR1 inhibits inflammasome activation by limiting potassium efflux during mycobacterial infection		1